AbbVie won the awards in the Research and Development (R&D) category within Gastrointestinal (GI) and Central Nervous System (CNS) therapy areas.
R&D Excellence in Gastrointestinal
AbbVie’s significant strides in GI research have been highlighted by dermatology drug Skyrizi, which has also shown positive outcomes in a late-stage clinical trial for ulcerative colitis. The Phase 3 maintenance study of risankizumab (SKYRIZI®) met its primary and key secondary endpoints at week 52, demonstrating clinical remission in patients who responded to induction treatment.
The trial’s success was marked by a higher proportion of patients achieving clinical remission, endoscopic improvement, histologic endoscopic mucosal improvement, and steroid-free remission after one year, compared to those who withdrew from the treatment. The safety results echoed the established safety profile of risankizumab, with no new risks identified.
As part of AbbVie’s expanding gastroenterology portfolio, risankizumab is an IL-23 inhibitor being evaluated for adults with moderate to severe ulcerative colitis and is already approved for Crohn’s disease, psoriatic arthritis, and psoriasis.
Dr. Stefan Schreiber, a clinical study investigator, praised the therapy’s potential to alleviate the disruptive symptoms of ulcerative colitis, highlighting its achievement in reaching a broad range of challenging endpoints.
R&D Excellence in CNS
AbbVie has made a significant impact with the European approval of AQUIPTA and US FDA approval of QULIPTA® (atogepant) for the preventive treatment of migraine in adults. AQUIPTA®, the first once-daily oral CGRP receptor antagonist in the EU, is approved for patients with four or more migraine days per month.
Atogepant, marketed as QULIPTA® in the US and Canada, is now the only oral CGRP receptor antagonist approved for both chronic and episodic migraine prevention. The FDA approval of QULIPTA® for chronic migraine is a testament to AbbVie’s leadership in migraine treatment, making it the only company with three prescription treatments designed to meet patient needs across the full spectrum of migraine.
AbbVie has established itself as a leader in the pharmaceutical industry, with its headquarters located in North Chicago, Illinois, US. The company’s dedication to innovative research and development has positioned it at the forefront of providing breakthrough therapies for some of the most challenging diseases.
1 N. Waukegan Road
North Chicago, Illinois 60064